TickerGuard
Buy Day today: Neutral (52) Mixed market breadth · major macro event coming up
RARE

Ultragenyx

Healthcare · Biotechnology

15.00$ -1.9% vs. previous close Closing price · As of: Sep 30, 2026

Statements

Income Statement

Ultragenyx (RARE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 214 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement RARE
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
98 127 109 147 139 165 139 166 160 207 136 214 717
11 12 18 21 21 17 29 23 28 29 30 34 121
87 115 91 126 118 148 111 143 132 178 106 180 596
157 161 178 162 170 188 166 165 216 203 187 167 773
75 77 78 81 80 82 88 87 87 88 88 88 351
232 237 257 242 250 270 254 251 303 292 275 255 1,125
-145 -122 -165 -116 -132 -122 -143 -108 -171 -114 -169 -75 -529
18 17 16 16 16 16 14 14 14 19 21 22 76
-159 -127 -170 -131 -133 -133 -150 -114 -180 -128 -184 -91 -583
0.7 -3.7 0.5 0.9 0.3 0.0 1.3 0.9 0.9 1.0 1.0 1.0 3.9
-160 -123 -171 -132 -134 -133 -151 -115 -180 -129 -185 -92 -586
-134 -101 -146 -106 -109 -109 -126 -91 -157 -100 -155 -61 -473

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?